Celldex Therapeutics Inc (NASDAQ:CLDX) price on current trading day, rose 12.76% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $22.95.
A look at the stock’s price movement, the level at last check in today’s session was $20.35, moving within a range at $20.0 and $24.03. The beta value (5-Year monthly) was 1.137. Turning to its 52-week performance, $47.00 and $14.40 were the 52-week high and 52-week low respectively. Overall, CLDX moved 21.15% over the past month.
Celldex Therapeutics Inc’s market cap currently stands at around $1.52 billion, with investors looking forward to this quarter’s earnings report slated for on 2025-May-07.
4 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 1 analyst(s) rate the stock as a Hold, 3 recommend CLDX as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
CLDX’s current price about 12.95% and 18.61% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 65.30, while 7-day volatility ratio is 1.87% and 3.51% in the 30-day chart. Further, Celldex Therapeutics Inc (CLDX) has a beta value of 1.14, and an average true range (ATR) of 1.42. Analysts have given the company’s stock an average 52-week price target of $46, forecast between a low of $46 and high of $46. Looking at the price targets, the low is -100.44% off recent price level in today’s trading while to achieve the yearly target high, it has to move -100.44%. Nonetheless, investors will most likely welcome a -100.44% jump to $46 which is the analysts’ median price.
If we refocus on Celldex Therapeutics Inc (NASDAQ:CLDX), historical trading data shows that trading volumes averaged 1.11 over the past 10 days and 885.43K over the past 3 months. The company’s latest data on shares outstanding shows there are 66.38 million shares.
The 2.84% of Celldex Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 109.39% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 8.37 million on 2025-05-30, giving us a short ratio of 9.24. The data shows that as of 2025-05-30 short interest in Celldex Therapeutics Inc (CLDX) stood at 1489.9999 of shares outstanding, with shares short falling to 9.01 million registered in 2025-04-30. Current price change has pushed the stock -9.20% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the CLDX stock continues to rise going into the next quarter.
